Determination of Cannabinoids in Oral Fluid Collected Using the Cozart® Oral Fluid Drug Test System

G Cooper
L Wilson
D Baldwin
C Hand

Cozart Bioscience Ltd, 45 Milton Park, Abingdon, Oxfordshire, OX14 4RU, UK

Roadside testing requires a simple but reliable test that can be carried out quickly and safely. Following changes in legislation allowing the collection and in some instances testing of oral fluid by the roadside, the Cozart® RapiScan is currently undergoing assessment in pilot studies in a number of different countries.

The use of the Cozart® RapiScan with integrated hand-held analyzer, has been shown over the past four years to be an effective means of performing on-site testing. Studies have shown the system to have similar accuracy to laboratory screening methods 1-4, when used in both clinical and criminal justice settings.

The analysis of cannabinoids in biological matrices is one of the greatest challenges for toxicologists and oral fluid is certainly no exception. With special emphasis on cannabinoids, this paper examines the findings of the different roadside pilot studies with respect to the prevalence of cannabinoids in this sample population and compares this to samples collected from individuals in drug treatment clinics. A further assessment of the Cozart® RapiScan’s ability to detect cannabinoids in oral fluid was carried out through comparison to laboratory tests (immunoassay and Gas Chromatography-Mass Spectrometry).